Hello,

We noticed you're browsing in private or incognito mode.

To continue reading this article, please exit incognito mode or log in.

Not an Insider? Subscribe now for unlimited access to online articles.

Rewriting Life

MicroRNA Diagnostics

The first diagnostic test to classify cancers by differences in microRNAs–small pieces of RNA that regu­late genes–will soon be on the market. The test distinguishes two types of lung cancer and should help doctors tailor treatments to their patients’ needs. Scientists say that tests based on microRNA profiles could prove more sensitive and reliable than existing methods, whose accuracy depends heavily on the judgment of the people analyzing them.

Product: MicroRNA test for lung cancer

Cost: Comparable to that of other molecular tests for cancer, which are priced at around $3,000 to $3,500

This story is part of our September/October 2008 Issue
See the rest of the issue
Subscribe

Source: rosettagenomics.com

Company: Rosetta Genomics

Uh oh–you've read all of your free articles for this month.

Insider Premium
$179.95/yr US PRICE

More from Rewriting Life

Reprogramming our bodies to make us healthier.

Want more award-winning journalism? Subscribe to Insider Basic.
  • Insider Basic {! insider.prices.basic !}*

    {! insider.display.menuOptionsLabel !}

    Six issues of our award winning print magazine, unlimited online access plus The Download with the top tech stories delivered daily to your inbox.

    See details+

    What's Included

    Unlimited 24/7 access to MIT Technology Review’s website

    The Download: our daily newsletter of what's important in technology and innovation

    Bimonthly print magazine (6 issues per year)

/
You've read all of your free articles this month. This is your last free article this month. You've read of free articles this month. or  for unlimited online access.